AFT Study Finds Some Prostate Cancer Drugs Related to More Cognitive Decline
A new randomized Alliance Foundation Trials (AFT) clinical study found that men with advanced prostate cancer taking the hormone therapy medication darolutamide had less cognitive decline compared to men taking enzalutamide. According to results from the ARACOG (AFT-47) phase II trial, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2026,…